Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Courtney V Fletcher

Showing results (111-120 of 162) with videos related to

Pageof 17
Sort By:
Contraception|February 14, 2023
Effect of double-dose levonorgestrel subdermal implant in women taking efavirenz-based antiretroviral therapy: The DoubLNG pharmacokinetic studyLauren R Cirrincione, Shadia Nakalema, Catherine A Chappell, et al.
The Journal of Infectious Diseases|August 27, 2002
Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359Roy M Gulick, X Joan Hu, Susan A Fiscus, et al.
World Journal of Gastroenterology|August 27, 2021
Therapeutic implications of SARS-CoV-2 dysregulation of the gut-brain-lung axisSamuel D Johnson, Omalla A Olwenyi, Namita Bhyravbhatla, et al.
AIDS (London, England)|July 20, 2002
Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in UgandaLaura A Guay, Philippa Musoke, David L Hom, et al.
Frontiers in Immunology|December 5, 2022
Morphine suppresses peripheral responses and transforms brain myeloid gene expression to favor neuropathogenesis in SIV infectionHoward S Fox, Meng Niu, Brenda M Morsey, et al.
Antimicrobial Agents and Chemotherapy|November 21, 2007
Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infectionJennifer J Kiser, Courtney V Fletcher, Patricia M Flynn, et al.
Elife|January 23, 2026
Doubling dolutegravir dosage reduces the viral reservoir in ART-treated people with HIVCéline Fombellida-Lopez, Aurelija Valaitienė, Lee Winchester, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Doubling dolutegravir dosage reduces the viral reservoir in ART-treated people with HIVCéline Fombellida-Lopez, Aurelija Valaitienė, Lee Winchester, et al.
Clinical Pharmacology and Therapeutics|July 7, 2022
Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS-CoV-2 InfectionRachel A Bender Ignacio, David A Wohl, Rosalin Arends, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 13, 2020
Brief Report: Sex Differences in Outcomes for Individuals Presenting for Third-Line Antiretroviral TherapyCatherine Godfrey, Michael D Hughes, Justin Ritz, et al.
Pageof 17

Showing results (111-120 of 162) with videos related to

Sort By:
Pageof 17
Contraception|February 14, 2023
Effect of double-dose levonorgestrel subdermal implant in women taking efavirenz-based antiretroviral therapy: The DoubLNG pharmacokinetic studyLauren R Cirrincione, Shadia Nakalema, Catherine A Chappell, et al.
The Journal of Infectious Diseases|August 27, 2002
Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359Roy M Gulick, X Joan Hu, Susan A Fiscus, et al.
World Journal of Gastroenterology|August 27, 2021
Therapeutic implications of SARS-CoV-2 dysregulation of the gut-brain-lung axisSamuel D Johnson, Omalla A Olwenyi, Namita Bhyravbhatla, et al.
AIDS (London, England)|July 20, 2002
Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in UgandaLaura A Guay, Philippa Musoke, David L Hom, et al.
Frontiers in Immunology|December 5, 2022
Morphine suppresses peripheral responses and transforms brain myeloid gene expression to favor neuropathogenesis in SIV infectionHoward S Fox, Meng Niu, Brenda M Morsey, et al.
Antimicrobial Agents and Chemotherapy|November 21, 2007
Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infectionJennifer J Kiser, Courtney V Fletcher, Patricia M Flynn, et al.
Elife|January 23, 2026
Doubling dolutegravir dosage reduces the viral reservoir in ART-treated people with HIVCéline Fombellida-Lopez, Aurelija Valaitienė, Lee Winchester, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Doubling dolutegravir dosage reduces the viral reservoir in ART-treated people with HIVCéline Fombellida-Lopez, Aurelija Valaitienė, Lee Winchester, et al.
Clinical Pharmacology and Therapeutics|July 7, 2022
Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS-CoV-2 InfectionRachel A Bender Ignacio, David A Wohl, Rosalin Arends, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 13, 2020
Brief Report: Sex Differences in Outcomes for Individuals Presenting for Third-Line Antiretroviral TherapyCatherine Godfrey, Michael D Hughes, Justin Ritz, et al.
Pageof 17